Celgene to Acquire Delinia with Goal of Moving Immunotherapy for Lupus into Testing – Lupus News Today
|
Celgene to Acquire Delinia with Goal of Moving Immunotherapy for Lupus into Testing
Lupus News Today Celgene Corporation announced that it has entered into an agreement to acquire Delinia, a biotech developing therapeutics for autoimmune diseases, including systemic lupus erythematosus (SLE). The acquisition will expand Celgene's inflammation and … |
